Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 29;32(3):439–447. doi: 10.3346/jkms.2017.32.3.439

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Korean Academy of Medical Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — Comparisons of pulmonary function in ACOS patients with different disease severity and control group before and after treatment.

ACOS = asthma-chronic obstructive pulmonary disease overlap syndrome, A = mild ACOS group, B = moderate ACOS group, C = severe ACOS group, D = extremely severe ACOS group, FEV1%pred = percentage of forced expiratory volume in 1 second (FEV1) to predicted value, FEV1/FVC = the ratio of FEV1 to forced vital capacity, IC/TLC = ratio of inspiratory capacity to total lung capacity, RV/TLC = ratio of residual volume to total lung capacity, Before = before the 6-month treatment, After = after the 6-month treatment.

^*P < 0.05, compared with the control group before treatment; ^†P < 0.05, compared with the control group after treatment; ^‡P < 0.05 when compared with the mild ACOS, moderate ACOS, severe ACOS, extremely severe ACOS, and control groups before treatment.